POZEN Inc. (NASDAQ: POZN)a pharmaceutical company committed to transforming medicine that transforms lives announced today that it plans to release fourth quarter and year end 2012 results on March 6 2013 before the market opens.
The announcement will be followed by a live webcast at 11:00 a.m. (ET) with a discussion by POZEN management of the earnings and business results. The webcast can be accessed on POZEN’s website at www.pozen.com and will be archived and available for replay. The fourth quarter and year end 2012 earnings release will be accessible in the Media section of POZEN’s website.
POZEN Inc. is a progressive pharmaceutical company that is transforming how the healthcare industry addresses unmet medical needs. By utilizing a unique in-source model and focusing on integrated therapies POZEN has successfully developed and obtained FDA approval of two self-invented products in two years. Funded by these milestone/royalty streams POZEN is now creating a portfolio of cost-effective evidence based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.
POZEN is currently seeking strategic partners to help maximize the opportunity for its portfolio assets.
The Company's common stock is traded under the symbol “POZN” on The NASDAQ Global Market. For more detailed company information including copies of this and other press releases please visit www.pozen.com.
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements which are based on current market data and research (including third party and POZEN sponsored market studies and reports) management’s current expectations and are subject to a number of risks and uncertainties including but not limited to our inability to license our PA product candidates on terms and timing acceptable to us our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates including as a result of the need to conduct additional studies or the failure to obtain such approval of our product candidates including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials resulting in among other things an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into and the risks resulting from our dependence upon collaboration or contractual arrangements necessary for the development manufacture commercialization marketing sales and distribution of any products including our dependence on AstraZeneca for the sales and marketing of VIMOVO™; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events including those discussed herein and in our Quarterly Report on Form 10-Q for the period ended September 31 2012. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.Business Wire
Last updated on: 27/02/2013
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.